|Description||CH5138303 is a novel and potent Hsp90 inhibitor. CH5138303 showed high binding affinity for N-terminal Hsp90α (Kd=0.52nM) and strong in vitro cell growth inhibition against human cancer cell lines (HCT116 IC50=0.098μM, NCI-N87 IC50=0.066μM) and also displayed high oral bioavailability in mice (F=44.0%) and potent antitumor efficacy in a human NCI-N87 gastric cancer xenograft model (tumor growth inhibition=136%).|
|Brife Description||CH5138303 is an orally available Hsp90 inhibitor with Kd of 0.48 nM.|
|Appearance||White solid powder|
|Synonyms||CH-5138303; CH 5138303|
|Solubility||DMSO: 83 mg/mL|
|Storage||3 years -20oC powder, 6 months-80oC in solvent.|
Retaspimycin(IPI 504) is a small-molecule inhibitor of heat shock protein 90 (Hsp90) with antiproliferative and antineoplastic activities.Retaspimycin binds to ...
Nanoparticle albumin-bound 17-AAG
XL888 is an ATP-competitive inhibitor of Hsp90. Through this action, specific client proteins are degraded, leading to cell cycle arrest or apoptosis. XL888 is ...
SST0116CL1 is a second-generation small molecule inhibitor of Hsp90, which leads to decreased expression of Hsp90 client proteins and reduced tumor cell prolife...
DS-2248 is an orally active and small molecule inhibitor of Hsp90, with potential antineoplastic activity. Upon oral administration, Hsp90 inhibitor DS-2248 spe...
Geldanamycin is a benzoquinone ansamycin antibiotic that binds to Hsp90 (Heat Shock Protein 90) and inhibits its function. Hsp90 client proteins play important ...
PU-H71 trihydrochloride is a potent inhibitor of heat shock protein 90 (Hsp90) (IC50 = 51 nM) that inhibits cell growth and induces cell apoptosis in triple-neg...
Novobiocin is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the interaction of both p23 and Hsp70 co-chaperones ...
Coumemycin A1 is found to bind at a second ATP-binding site in the C-terminal domain of Hsp90, thus disrupting the dimerization of the Hsp90 complex.IC50 70μmol...
EC 114 is a high affinity, potent and selective Hsp90 inhibitor. IC50 1.1 nM. It exhibits selectivity for Hsp90 over Grp94 and TRAP1 (Ki values are 61 and 255 n...
Macbecin I is an ansamycin antibiotic compound that inhibits Hsp90 by binding to the ATP-binding site.IC50 = 2μM. Exhibits antitumor and cytocidal activities (I...
Gambogic acid is a natural product inhibitor of Hsp90.
WK88-1 inhibits Hsp90, resulting in decreased expression of Hsp90 client proteins and potentially leading to decreased tumor cell growth.
17-AAG hydrochloride is a potent HSP90 inhibitor with IC50 value of 5 nM, which is a 100-fold higher binding affinity for HSP90 derived from tumour cells than t...
Triolimus is a composed of a micelle containing the drugs rapamycin, 17-AAG, and paclitaxel, which act synergistically to inhibit tumor growth
G-TPP is a mitochondria-targeted Hsp90 inhibitor that increases cell death in HeLa and MCF7 cells, consistently inhibits cell death induced by oxidative stress ...
Pochocin A is a patent Hsp90 inhibitor. IC50 90nM.
Radester is a hybrid composed of radicicol's resorcinol and geldanamycin’s benzoquinone part structures and exhibits good cellular activity against MCF7 breast ...
PU-WS13 is a cell-permeable inhibitor of Grp94 (EC50 = 220 nM).It shows selectivity for Grp94 over the related Hsps Trap-1, Hsp90α, and Hsp90β. PU-WS13 blocks t...
CPUY201112 is an N-terminal Hsp90 inhibitor, which leads to decreased expression of Hsp90 client proteins and may result in increased tumor cell apoptosis.